Boston Scientific Co. (NYSE:BSX) EVP John Bradley Sorenson Sells 6,389 Shares

Boston Scientific Co. (NYSE:BSX - Get Free Report) EVP John Bradley Sorenson sold 6,389 shares of the stock in a transaction that occurred on Wednesday, February 12th. The shares were sold at an average price of $105.06, for a total transaction of $671,228.34. Following the completion of the transaction, the executive vice president now owns 24,293 shares in the company, valued at $2,552,222.58. This represents a 20.82 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

John Bradley Sorenson also recently made the following trade(s):

• On Friday, February 7th, John Bradley Sorenson sold 6,528 shares of Boston Scientific stock. The shares were sold at an average price of $104.97, for a total transaction of $685,244.16.
• On Thursday, January 2nd, John Bradley Sorenson sold 4,119 shares of Boston Scientific stock. The shares were sold at an average price of $90.02, for a total transaction of $370,792.38.

Boston Scientific Price Performance

Shares of NYSE BSX traded up $0.06 during trading on Monday, hitting $106.20. 3,966,417 shares of the company were exchanged, compared to its average volume of 6,179,673. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.48 and a quick ratio of 1.02. Boston Scientific Co. has a 1 year low of $65.33 and a 1 year high of $107.17. The company has a market cap of $156.51 billion, a price-to-earnings ratio of 84.96, a PEG ratio of 2.79 and a beta of 0.80. The firm's fifty day moving average price is $96.44 and its 200 day moving average price is $88.39.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $0.70 EPS for the quarter, topping analysts' consensus estimates of $0.65 by $0.05. Boston Scientific had a net margin of 11.07% and a return on equity of 18.11%. On average, sell-side analysts expect that Boston Scientific Co. will post 2.83 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Boston Scientific

A number of institutional investors and hedge funds have recently modified their holdings of the company. Norges Bank purchased a new stake in shares of Boston Scientific in the fourth quarter valued at about $1,762,522,000. Capital World Investors raised its position in shares of Boston Scientific by 28.7% during the 4th quarter. Capital World Investors now owns 27,899,903 shares of the medical equipment provider's stock worth $2,492,041,000 after purchasing an additional 6,216,199 shares during the last quarter. Wellington Management Group LLP lifted its stake in Boston Scientific by 10.2% in the 4th quarter. Wellington Management Group LLP now owns 36,165,399 shares of the medical equipment provider's stock valued at $3,230,293,000 after buying an additional 3,344,571 shares in the last quarter. AustralianSuper Pty Ltd grew its holdings in Boston Scientific by 4,292.3% during the 3rd quarter. AustralianSuper Pty Ltd now owns 2,676,847 shares of the medical equipment provider's stock valued at $224,320,000 after buying an additional 2,615,903 shares during the last quarter. Finally, Axiom Investors LLC DE increased its position in Boston Scientific by 208.2% during the fourth quarter. Axiom Investors LLC DE now owns 3,752,430 shares of the medical equipment provider's stock worth $335,167,000 after buying an additional 2,535,007 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company's stock.

Analyst Ratings Changes

A number of analysts have recently commented on the company. Truist Financial lifted their target price on Boston Scientific from $100.00 to $110.00 and gave the stock a "buy" rating in a research report on Wednesday, December 18th. TD Cowen lifted their price target on Boston Scientific from $100.00 to $110.00 and gave the stock a "buy" rating in a research report on Thursday, December 12th. Raymond James increased their price objective on Boston Scientific from $119.00 to $122.00 and gave the company a "strong-buy" rating in a report on Thursday, February 6th. Bank of America lifted their target price on shares of Boston Scientific from $90.00 to $100.00 and gave the company a "buy" rating in a report on Tuesday, October 22nd. Finally, Barclays increased their price target on shares of Boston Scientific from $111.00 to $118.00 and gave the stock an "overweight" rating in a research note on Monday, February 10th. One equities research analyst has rated the stock with a hold rating, twenty-two have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Boston Scientific currently has an average rating of "Buy" and an average target price of $107.39.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.